Cancer Chemoprevention: Volume 2: Strategies for Cancer Chemoprevention

ISBN-13: 9781588290779 / Angielski / Mixed media product / 2005 / 543 str.

Gary J. Kelloff; Ernest T. Hawk; Caroline C. Sigman

Opis

Despite significant advances in cancer treatment and measures of neoplastic progression, drug effect (or early detection, overall cancer incidence has increased, pharmacodynamic markers), and markers that measure cancer-associated morbidity is considerable, and overall prognosis as well as predict responses to specific therapy. cancer survival has remained relatively flat over the past All these biomarkers have the potential to greatly augment several decades (1,2). However, new technology the development of successful chemoprevention therapies, allowing exploration of signal transduction pathways, but two specific types of biomarkers will have the most identification of cancer-associated genes, and imaging of immediate impact on successful chemopreventive drug tissue architecture and molecular and cellular function is development those that measure the risk of developing increasing our understanding of carcinogenesis and cancer invasive life-threatening disease, and those whose mo- progression. This knowledge is moving the focus of cancer lation can reasonably predict clinical benefit and, therapeutics, including cancer preventive treatments, to therefore, serve as surrogate endpoints for later-occurring drugs that take advantage of cellular control mechanisms clinical disease. Thus far, the biomarker that best measures to selectively suppress cancer progression. these two phenomena is intraepithelial neoplasia (IEN) Carcinogenesis is now visualized as a multifocal, because it is a near obligate precursor to cancer."

Recenzje

"...comprehensive review of the literature concerning current and future cancer chemoprevention strategies... provide(s) a basis for future developments." - The Annals of Pharmacology

"...a good reference source for students and experts alike who are interested in evaluating cancer risk, strategies available to try to prevent certain cancers developing and how the incidence of cancer can be reduced b the use of therapeutic agents. -Newletter of the British Toxicology Society

Spis treści

Part I. Chemopreventive Agent Development Science Characterization of Natural Product Chemopreventive Agents John M. Pezzuto, Jerome W. Kosmeder II, Eun-Jung Park, Sang Kook Lee, Muriel Cuendet, Joell Gills, Krishna Bhat, Simonida Grubjesic, Hye-Sung Park, Eugenia Mata-Greenwood, YingMeei Tan, Rong Yu, Daniel D. Lantvit, and A. Douglas Kinghorn Preclinical Animal Models for the Development of Cancer Chemoprevention Drugs Vernon E. Steele, Ronald A. Lubet, and Richard C. Moon Potential Use of Transgenic Mice in Chemoprevention Studies Ronald A. Lubet, Jeffrey Green, Vernon E. Steele, and Ming You Modeling Human Colorectal Cancer in Mice for Chemoprevention Studies Martin Lipkin and Sergio A. Lamprecht Pathology of Incipient Neoplasia Donald Earl Henson and Jorge Albores-Saavedra Quantitative Nuclear Grade: Clinical Applications of the Quantitative Measurement of Nuclear Structure Using Image Analysis Robert W. Veltri, Alan W. Partin, and M. Craig Miller Enabling Discovery Through Online Cancer Genome Databases and Analytic Tools Robert L. Strausberg and Gregory J. Riggins Functional Genomics for Identifying Surrogate Endpoint Biomarkers in Breast Cancer Chemoprevention Melissa A. Troester and Charles M. Perou Clinical Applications of Proteomics Emanuel F. Petricoin III and Lance A. Liotta Bioinformatics and Whole-Genome Technologies Richard Simon Models of Absolute Risk: Uses, Estimation, and Validation Mitchell H. Gail Genetic Polymorphisms and Risk Assessment for Cancer Chemoprevention Sonia de Assis and Peter G. Shields Design Issues in Prostate Cancer Chemoprevention Trials: Lessons From the Prostate Cancer Prevention Trial Ian M. Thompson and Charles A. Coltman Jr. Recruitment Strategies for Cancer Prevention Trials Paul P. Carbone, Karen Sielaff, Mary Hamielec, and Howard Bailey Part II. Cancer Chemoprevention at Major Cancer Target Sites Prostate Prostate Cancer Prevention William G. Nelson, Angelo M. de Marzo, and Scott M. Lippman Use of PSA to Evaluate Risk and Progression of Prostate Cancer Bulent Akduman, Abelardo Errejon, and E. David Crawford Breast Clinical Approaches to Discovering and Testing New Breast Cancer Prevention Drugs Carol J. Fabian, Bruce F. Kimler, Matthew S. Mayo, William E. Grizzle, Shahla Masood, and Giske Ursin Ductal Lavage: Its Role in Breast Cancer Risk Assessment and Risk Reduction Joyce O'Shaughnessy and Andrea Decensi Counteracting Estrogen as Breast Cancer Prevention Kathrin Strasser-Weippl and Paul E. Goss Colorectal Chemoprevention of Colorectal Cancer: Clinical Strategies Monica M. Bertagnolli and Stanley R. Hamilton Screening in Risk Evaluation and Prevention of Colorectal Cancer Bernard Levin Lung Strategies in Lung Cancer Chemoprevention Edward S. Kim, Faye M. Johnson, Waun Ki Hong, and Fadlo R. Khuri Lung Cancer Chemoprevention: An Opportunity for Direct Drug Delivery James L. Mulshine and Luigi M. De Luca Bladder Bladder Cancer: Clinical Strategies for Cancer Chemoprevention H. Barton Grossman, Anita L. Sabichi, and Yu Shen Esophagus Barrett's Esophagus: Strategies for Cancer Prevention Brian J. Reid Endoscopic Detection of Esophageal Neoplasia Brian C. Jacobson and Jacques Van Dam Chemoprevention Strategies for Esophageal Squamous Cell Carcinoma Paul J. Limburg, Philip R. Taylor, and Sanford M. Dawsey Head and Neck Chemoprevention of Upper Aerodigestive Tract Cancer: Clinical Trials and Future Directions Fadlo R. Khuri, Edward S. Kim, and Waun Ki Hong Chemoprevention of Oral Cancer: Ri

Blurb

Much progress has been made in discovering and developing agents that have promise, or have already been successfully used, to treat precancerous conditions or inhibit carcinogenesis. In Cancer Chemoprevention, Volume 2: Strategies for Cancer Chemoprevention, leading chemopreventives investigators comprehensively describe the exciting methodologies that are accelerating progress in the chemoprevention field and review the state of clinical development of preventive agents in the major human cancer target organs. The authors provide sound guidelines for cancer chemopreventive drug development, detailing general strategies and methods for drug discovery, preclinical efficacy, characterization of precancers, safety evaluation of clinical cohorts, and clinical trial design. Additional chapters address strategies for and the status of chemopreventive agent development in multiple myeloma and cancers of the prostate, breast, lung, colon, bladder, head and neck, esophagus, pancreas, ovary, endometrium, cervix, skin, and liver. The emphasis is on documenting the characterization and application of reliable biomarkers during chemopreventive drug development. Highlights include an elegant approach to identifying chemopreventive agents in natural products, the development of preclinical models for evaluating potential chemopreventive agents, the genomics and proteomics of potential applications, and approaches for determining which populations will likely benefit from chemopreventive intervention. A companion volume, Promising Cancer Chemopreventive Agents, comprehensively surveys those agents that have promise, or have already been successfully used, to treat precancerous conditions or inhibit carcinogenesis. A value-added compact disk containing a companion ebook version of Cancer Chemoprevention, Volume 2: Strategies for Cancer Chemoprevention is included for downloading and use in the reader's PC or PDA.
Up-to-date and highly practical, Cancer Chemoprevention, Volumes 1 & 2, offer oncologists, pharmacologists, medicinal chemists, and toxicologists a comprehensive reference survey on the identification of those promising cancer chemopreventive agents that will help stimulate further research and the development of novel approvable drugs.